Skip to main content
. 2018 Feb 21;3(3):297–304. doi: 10.1016/j.adro.2018.02.005

Table 1.

Patient and treatment characteristics by severity of hematologic toxicity

Characteristic No HT3+
HT3+
P-valuea
n (%) n (%)
Total 39 100.0 21 100.0
Sex .606
 Female 2 5.1 2 9.5
 Male 37 94.9 19 90.5
Histology .039
 Adenocarcinoma 39 100.0 18 85.7
 Squamous cell carcinoma 0 0.0 2 9.5
 Adenosquamous 0 0.0 1 4.8
Stage .326
 IB 2 5.1 0 0.0
 IIA 6 15.4 2 9.5
 IIB 7 17.9 4 19.0
 IIIA 20 51.3 9 42.9
 IIIB 2 5.1 2 9.5
 IIIC 1 2.6 0 0.0
 IV 0 0.0 3 14.3
 N/A 1 2.6 1 4.8
Treatment intent .143
 Neoadjuvant 35 89.7 15 71.4
 Definitive 4 10.3 6 28.6
Radiation therapy modality .119
 IMRT 39 100.0 19 90.5
 3-dimensional CRT 0 0.0 2 9.5
Concurrent chemotherapy .154
 Carboplatin and paclitaxel 29 74.4 12 57.1
 5-FU/capecitabine with platinum agent 8 20.5 9 42.9
 5-FU/capecitabine alone 2 5.1 0 0.0

5-FU, 5-flurouracil; CRT, conformal radiation therapy; HT3+, grade ≥3 hematologic toxicity; IMRT, intensity modulated radiation therapy.

a

Fisher's exact test P-value.